Update of the position paper of the Spanish Society of Rheumatology on biosimilar drugs

Kelly, 2009, Economics of biological therapies, BMJ., 339, 10.1136/bmj.b3276 http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/general/general_content_001832.jsp (accessed 1 Sep 2018). Abad Hernández, 2015, Reumatol Clin, 11, 269, 10.1016/j.reuma.2015.03.009 Los Biosimilares en la UE. Guía informativa para profesionales sanitarios. http://www.ema.europa.eu/docs/es_ES/document_library/Leaflet/2017/05/WC500226648.pdf ( acceso 17-09-18). Gámez-Belmonte, 2018, Biosimilars: Concepts and controversies, Pharmacol Res., 133, 251, 10.1016/j.phrs.2018.01.024 Socinski, 2015, Clinical considerations for the development of biosimilars in oncology, MAbs, 7, 286, 10.1080/19420862.2015.1008346 US Department of Health and Human Services. Scientific considerations in demonstrating biosimilarity to a reference product. Guidance for industry. http://www.fda.gov/downloads/drugs/ guidancecomplianceregulatoryinformation/guidances/ucm291128.pdf. acceso 11-09-2018). Alten, 2015, Clinical trial development for biosimilars, Semin Arthritis Rheum, 44, S2, 10.1016/j.semarthrit.2015.04.002 Dranitsaris, 2011, Biosimilars of biological drug therapies: regulatory, clinical and commercial considerations, Drugs, 71, 1527, 10.2165/11593730-000000000-00000 European Medicines Agency [internet], 2014 World Health Organization [internet], 2009 Weise, 2014, Biosimilars: the science of extrapolation, Blood, 124, 3191, 10.1182/blood-2014-06-583617 Emery, 2017, 52-week results of the phase 3 randomized study comparing SB4 with reference etanercept in patients with active rheumatoid arthritis, Rheumatology (Oxford), 56, 2093, 10.1093/rheumatology/kex269 European Medicines Agency [internet], 2009 Choe, 2017, A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy, Ann Rheum Dis, 76, 58, 10.1136/annrheumdis-2015-207764 Yoo, 2013, A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study, Ann Rheum Dis, 72, 1613, 10.1136/annrheumdis-2012-203090 Park, 2013, A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study, Ann Rheum Dis, 72, 1605, 10.1136/annrheumdis-2012-203091 European Medicines Agency [internet], 2013 European Medicines Agency [internet], 2013 Generics and Biosimilars Initiative (GaBI) Online [internet], 2014 Health Canada [internet], 2014 Health Canada [internet], 2014 Pfizer Canada Inc. [internet]. Health Canada Approves Inflectra® (biosimilar infliximab) for three additional indications: Crohn’s disease, fistulising Crohn’s disease and ulcerative colitis. [updated June 14, 2016]. Available from: http://www.pfizer.c a/node/7526. Dorner, 2015, Biosimilars in rheumatology: current perspectives and lessons learnt, Nat Rev Rheumatol, 11, 713, 10.1038/nrrheum.2015.110 Ebbers, 2014, Biosimilars: in support of extrapolation of indications, J Crohns Colitis, 8, 431, 10.1016/j.crohns.2014.02.007 Feldman, 2015, Inflammatory diseases: Integrating biosimilars into clinical practice, Semin Arthritis Rheum, 44, S16, 10.1016/j.semarthrit.2015.04.003 American College of Rheumatology [internet], 2015 Danese, 2013, Governing Board and Operational Board of ECCO. ECCO position statement: the use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD), J Crohns Colitis, 7, 586, 10.1016/j.crohns.2013.03.011 Avila-Ribeiro, 2017, The experience with biosimilars of infliximab in inflammatory bowel disease, Curr Pharm Des, 23, 6759, 10.2174/1381612824666171204095342 Gecse, 2016, Efficacy and safety of the biosimilar infliximab CT-P13 Treatment in inflammatory bowel diseases: a prospective, multicentre, nationwide cohort, J Crohn’s Colitis., 10, 133, 10.1093/ecco-jcc/jjv220 Fiorino, 2017, The PROSIT-BIO Cohort: A Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Infliximab Biosimilar, Inflamm Bowel Dis, 23, 10.1097/MIB.0000000000000995 Komaki, 2017, Systematic review with meta-analysis: the efficacy and safety of CT-P13, a biosimilar of anti-tumour necrosis factor-α agent (infliximab), in inflammatory bowel diseases, Aliment Pharmacol Ther., 45, 1043, 10.1111/apt.13990 Radin, 2017, Infliximab Biosimilars in the Treatment of Inflammatory Bowel Diseases: A Systematic Review, BioDrugs., 31, 37, 10.1007/s40259-016-0206-1 Lo que debe saber sobre los medicamentos Bosimilares. EMA/83780572011) de 27 de septiembre de 2012. https://ec.europa.eu/docsroom/documents/8242/attachments/1/translations/es/…/native. Qué necesito saber sobre los Biosimilares Información para pacientes. https://ec.europa.eu/docsroom/documents/8242/attachments/1/translations/es/…/native. Faccin, 2016, The design of clinical trials to support the switching and alternation of biosimilars, Expert Opin Biol Ther., 16, 1445, 10.1080/14712598.2017.1238454 Yoo, 2017, Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study, Ann Rheum Dis., 76, 355, 10.1136/annrheumdis-2015-208786 Park, 2017, Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study, Ann Rheum Dis., 76, 346, 10.1136/annrheumdis-2015-208783 Smolen, 2018, Safety, immunogenicity and efficacy after switching from reference infliximab to biosimilar SB2 compared with continuing reference infliximab and SB2 in patients with rheumatoid arthritis: results of a randomised, double-blind, phase III transition study, Ann Rheum Dis., 77, 234, 10.1136/annrheumdis-2017-211741 Emery, 2017, Long-term efficacy and safety in patients with rheumatoid arthritis continuing on SB4 or switching from reference etanercept to SB4, Ann Rheum Dis., 10.1136/annrheumdis-2017-211591 Griffiths, 2017, EGALITY study: A confirmatory, randomised, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, versus the originator product in patients with moderate to severe chronic plaque-type psoriasis, Br J Dermatol., 176, 928, 10.1111/bjd.15152 Zhao, 2018, Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis, Curr Rheumatol Rep, 20 Nikiphorou, 2015, Clinical effectiveness of CT-P13 (Infliximab biosimilar) used as a switch from Remicade (infliximab) in patients with established rheumatic disease. Report of clinical experience based on prospective observational data, Expert Opin Biol Ther., 15, 1677, 10.1517/14712598.2015.1103733 Abdalla, 2017, Long-term safety and efficacy of biosimilar infliximab among patients with inflammatory arthritis switched from reference product, Open Access Rheumatol., 9, 29, 10.2147/OARRR.S124975 Malaiya, 2016, Infliximab Biosimilars—Switching Remicade to Remsima in Routine Care: Patient Acceptability and Early Outcome Data, Rheumatology, 55, i125 Batticciotto, 2016, Safety and Efficacy of Switching from Originator to CT-P13 Infliximab Biosimilar in Patients Affected By Spondyloarthritis. a 6-Month Observational Study [abstract], Arthritis Rheumatol., 68 Gentileschi S, Barreca C, Bellisai F, Biasi G, Brizi MG, De Stefano R et al. Switch from infliximab to infliximab biosimilar: efficacy and safety in a cohort of patients with different rheumatic diseases. Response to: Nikiphorou E, Kautiainen H, Hannonen P, et al. Clinical effectiveness of CT-P13 (Infliximab biosimilar) used as a switch from Remicade (infliximab) in patients with established rheumatic disease. Report of clinical experience based on prospective observational data. Expert Opin Biol Ther. 2015;15:1677-1683. Expert Opin Biol Ther. 2016;16:1311-2. Benucci, 2017, Safety, efficacy and immunogenicity of switching from innovator to biosimilar infliximab in patients with spondyloarthritis: a 6-month real-life observational study, Immunol Res., 65, 419, 10.1007/s12026-016-8843-5 Glintborg, 2017, A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry, Ann Rheum Dis, 76, 1426, 10.1136/annrheumdis-2016-210742 Vergara-Dangond, 2017, Effectiveness and Safety of Switching from Innovator Infliximab to Biosimilar CT-P13 in Inflammatory Rheumatic Diseases: A Real-World Case Study, Drugs R D, 17, 481, 10.1007/s40268-017-0194-8 Avouac, 2018, Systematic switch from innovator infliximab to biosimilar infliximab in inflammatory chronic diseases in daily clinical practice: The experience of Cochin University Hospital, Paris, France.Semin Arthritis Rheum., 47 Tweehuysen, 2018, Subjective Complaints as the Main Reason for Biosimilar Discontinuation After Open-Label Transition From Reference Infliximab to Biosimilar Infliximab, Arthritis Rheumatol., 70, 60, 10.1002/art.40324 Scherlinger, 2018, Switching from originator infliximab to biosimilar CT-P13 in real-life: The weight of patient acceptance, Joint Bone Spine., 85, 561, 10.1016/j.jbspin.2017.10.003 Holroyd, 2018, Switching to biosimilar infliximab: real world data in patients with severe inflammatory arthritis, Clin Exp Rheumatol., 36, 171 Szlumper, 2017, Switching Biosimilar etanercept in clinical practice, Rheumatology, 56 Rabbitts, 2017, Switching to biosimilars: an early clinical review, Rheumatology, 56 Sigurdardottir, 2017, Switching from reference product etanercpet to the biosimilar SB4 in a real-life setting: follow-up of 147 patients, Ann Rheum Diss, 76, 835 Holroyd, 2017, Switching from bio-original etanercept to biosimilar etanercept SB4: patient acceptability and outcomes in the real world, Ann Rheum Diss, 76, 1180 Dyball, 2017, Effectiveness and Tolerability of Benepali in Rheumatoid Arthritis Patients Switched from Enbrel, Arthritis Rheumatol., 69 Glintborg, 2017, One-Year Clinical Outcomes in 1623 Patients with Inflammatory Arthritis Who Switched from Originator to Biosimilar Etanercept – an Observational Study from the Danish Danbio Registry [abstract], Arthritis Rheumatol, 69 Hendricks, 2017, When Etanercept Switch Fails – Clinical Considerations, Arthritis Rheumatol., 69 Shah, 2018, Clinical outcomes of a multi-disciplinary switching programme to biosimilar etanercept for patients with rheumatoid arthritis, Rheumatology, 57 Patel, 2018, Analysis of rheumatoid arthritis patients who failed the switch from originator etanercept to biosimilar etanercept in Croydon, Rheumatology, 57 Smith, 2018, Similar experience of biosimilars: a review of Rotherham Hospital’s experience of switching from enbrel to benepali, Rheumatology, 57 Attipoe, 2018, What factors predict good patient experiences of switching from reference etanercept to an etanercept biosimilar in a South West London general hospital?, Rheumatology, 57 Tweehuysen, 2018, Open-Label, Non-Mandatory Transitioning From Originator Etanercept to Biosimilar SB4: Six-Month Results From a Controlled Cohort Study, Arthritis Rheumatol., 70, 1408, 10.1002/art.40516 Bingel, 2014, Avoiding nocebo effects to optimize treatment outcome, JAMA., 20, 693, 10.1001/jama.2014.8342 Planès, 2016, The nocebo effect of drugs, Pharmacol Res Perspect., 4, 10.1002/prp2.208 Kravvariti, 2018, Nocebos in rheumatology: emerging concepts and their implications for clinical practice, Nat Rev Rheumatol., 10.1038/s41584-018-0110-9 Jørgensen, 2017, Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial, Lancet., 389, 2304, 10.1016/S0140-6736(17)30068-5 Razanskaite, 2017, Biosimilar Infliximab in Inflammatory Bowel Disease: Outcomes of a Managed Switching Programme, J Crohns Colitis., 11, 690 Holroyd, 2016, Switching to Biosimilar Infliximab: Real-World Data from the Southampton Biologic Therapies Review Service, Rheumatology (Oxford), 55, i60 Kay, 2017, Pharmacotherapy: Biosimilar switching “To set a form upon desired change, Nat Rev Rheumatol., 10.1038/nrrheum.2017.79 Schellekens, 2003, Immunogenicity of therapeutic proteins, Nephrol Dial Transplant, 18, 1257, 10.1093/ndt/gfg164 Wolbink, 2009, Dealing with immunogenicity of biologicals: assessment and clinical relevance, Curr Opin Rheumatol, 21, 211, 10.1097/BOR.0b013e328329ed8b Chamberlain, 2013, Assessing immunogenicity of biosimilar therapeutic monoclonal antibodies: regulatory and bioanalytical considerations, Bioanalysis, 5, 561, 10.4155/bio.13.6 Strand, 2017, Immunogenicity of Biologics in Chronic Inflammatory Diseases: A Systematic Review, BioDrugs, 31, 299, 10.1007/s40259-017-0231-8 Ruiz-Arguello, 2016, Antibodies to infliximab in Remicade-treated rheumatic patients show identical reactivity towards biosimilars, Ann Rheum Dis, 75, 1693, 10.1136/annrheumdis-2015-208684 Ben-Horin, 2016, Cross-immunogenicity: antibodies to infliximab in Remicade-treated patients with IBD similarly recognise the biosimilar Remsima, Gut., 65, 1132, 10.1136/gutjnl-2015-309290 Reinisch, 2017, Evaluation of the Cross-reactivity of Antidrug Antibodies to CT-P13 and Infliximab Reference Product (Remicade): An Analysis Using Immunoassays Tagged with Both Agents, BioDrugs, 31, 223, 10.1007/s40259-017-0219-4 Fiorino, 2018, Full Interchangeability in Regard to Immunogenicity Between the Infliximab Reference Biologic and Biosimilars CT-P13 and SB2 in Inflammatory Bowel Disease, Inflamm Bowel Dis, 24, 601, 10.1093/ibd/izx086 Emery, 2017, A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy, Ann Rheum Dis., 76, 51, 10.1136/annrheumdis-2015-207588 Kavanaugh, 2017, Etanercept Biosimilar GP2015 Has Equivalent Efficacy and Safety to Etanercept Originator in Patients with Moderate to Severe Rheumatoid Arthritis: The Phase 3 Equira Study [abstract], Arthritis Rheumatol, 69 Aladul, 2017, Impact of infliximab and etanercept biosimilars on biological disease-modifying antirheumatic drugs utilisation and NHS budget in the UK, BioDrugs, 31, 533, 10.1007/s40259-017-0252-3 Jacobs, 2016, Patient attitudes and understanding about biosimilars: an international cross-sectional survey, Patient Prefer Adherence, 10, 937, 10.2147/PPA.S104891 Attara, 2016, Canadian patient and caregiver perspectives on subsequent entry biologics/biosimilars for inflammatory bowel disease, Gastroenterology, 150, S443, 10.1016/S0016-5085(16)31540-2 Wilkins, 2014, Patient perspectives on biosimilar insulin, J Diabetes Sci Technol, 8, 23, 10.1177/1932296813515132 Beck, 2016, Rheumatologists’ perceptions of biosimilar medicines prescription: findings from a french web-based survey, BioDrugs, 30, 585, 10.1007/s40259-016-0202-5 Cohen, 2017, Awareness, knowledge, and perceptions of biosimilars among specialty physicians, Adv Ther, 33, 2160, 10.1007/s12325-016-0431-5 Waller, 2017, Assessing physician and patient acceptance of infliximab biosimilars in rheumatoid arthritis, ankylosing spondyloarthritis and psoriatic arthritis across Germany, Patient Prefer Adherence, 11, 519, 10.2147/PPA.S129333 Hemmington, 2017, Medical specialists’ attitudes to prescribing biosimilars, Pharmacoepidemiol Drug Saf, 26, 570, 10.1002/pds.4186 van Overbeeke, 2017, Perception of originator biologics and biosimilars: a survey among Belgian rheumatoid arthritis patients and rheumatologists, BioDrugs, 31, 447, 10.1007/s40259-017-0244-3 O’Callaghan, 2017, Assessing awareness and attitudes of healthcare professionals on the use of biosimilar medicines: A survey of physicians and pharmacists in Ireland, Regul Toxicol Pharmacol, 88, 252, 10.1016/j.yrtph.2017.06.013